Juvenile idiopathic arthritis-related uveitis

International Ophthalmology Clinics

Volumn 48, Issue 3, 2008, Pages 21-38

  Kesen, Muge R ^a   Setlur, Vikram ^a   Goldstein, Debra A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIMETABOLITE; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CORTICOSTEROID; CYCLOPLEGIC AGENT; CYCLOSPORIN; ETANERCEPT; FOLIC ACID; IBUPROFEN; INDOMETACIN; INFLIXIMAB; METHOTREXATE; MYDRIATIC AGENT; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; TOLMETIN; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALLERGIC PNEUMONITIS; ALOPECIA; ARTHRALGIA; ARTHRITIS; BLOOD DYSCRASIA; BONE MARROW SUPPRESSION; CATARACT; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSPEPSIA; ENTHESITIS; EYE INFLAMMATION; EYE SYNECHIA; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GLAUCOMA; HODGKIN DISEASE; HUMAN; HYPERSENSITIVITY; HYPERTRICHOSIS; INFECTION SENSITIVITY; INJECTION SITE PAIN; INTRAOCULAR HYPOTENSION; JUVENILE RHEUMATOID ARTHRITIS; KERATOPATHY; LIVER TOXICITY; LUPUS LIKE SYNDROME; MOUTH ULCER; NAUSEA; NEPHROTOXICITY; PARESTHESIA; PATHOGENESIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; SKIN NODULE; TEMPERATURE HYPERSENSITIVITY; URTICARIA; UVEITIS; VOMITING; WEIGHT REDUCTION; ADOLESCENT; CHILD; INFANT; PRESCHOOL CHILD;

ADOLESCENT; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; UVEITIS;

EID: 51649105233     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/IIO.0b013e31817d998f     Document Type: Review

References (112)

1. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol. 1998; 25:1991-1994.
2. Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.J Rheumatol. 2004; 31:390-392.
3. Kump LI, Cervantes-Castaneda RA, Androudi SN, et al. Analysis of pediatric uveitis cases at a tertiary referral center. Ophthalmology. 2005; 112:1287-1292.
4. Rosenberg KD, Feuer W J, Davis J L. Ocular complications of pediatric uveitis. Ophthalmology. 2004; 111:2299-2306.
5. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996; 80: 332-336.
6. Kotaniemi K, Savolainen A, Karma A, et al. Recent advances in uveitis of juvenile idiopathic arthritis. Surv Ophthalmol. 2003; 48:489-502.
7. Bowyer S, Roettcher P. Pediatric rheumatology clinic populations in the United States: results of a 3 year survey. Pediatric Rheumatology Database Research Group. J Rheumatol. 1996; 23:1968-1974.
8. Symmons DP, Jones M, Osborne J, et al. Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register.J Rheumatol. 1996; 23:1975-1980.
9. Malleson PN, Fung MY, Rosenberg AM. The incidence of pediatric rheumatic diseases: results from the Canadian Pediatric Rheumatology Association Disease Registry. J Rheumatol. 1996; 23:1981-1987.
10. Oen KG, Cheang M. Epidemiology of chronic arthritis in childhood. Semin Arthritis Rheum. 1996;26:575-591.
11. Petty RE, Smith JR, Rosenbaum JT. Arthritis and uveitis in children. A pediatric rheumatology perspective. Am J Ophthalmol. 2003; 135:879-884.
12. Kotaniemi K, Kautiainen H, Karma A, et al. Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Ophthalmology. 2001; 108: 2071-2075.
13. Guillaume S, Prieur AM, Coste J, et al. Long-term outcome and prognosis in oligoarticular-onset juvenile idiopathic arthritis. Arthritis Rheum. 2000; 43:1858-1865.
14. Chylack LT Jr. The ocular manifestations of juvenile rheumatoid arthritis. Arthritis Rheum. 1977;20(2 suppl):217-223.
15. Sherry DD, Mellins ED, Wedgwood RJ. Decreasing severity of chronic uveitis in children with pauciarticular arthritis. Am J Dis Child. 1991;145:1026-1028.
16. Cimaz RG, Fink CW. The articular prognosis of pauciarticular onset juvenile arthritis is not influenced by the presence of uveitis. J Rheumatol. 1996; 23:357-359.
17. Rosenberg AM, Oen KG. The relationship between ocular and articular disease activity in children with juvenile rheumatoid arthritis and associated uveitis. Arthritis Rheum. 1986; 29:797-800.
18. Chalom EC, Goldsmith DP, Koehler MA, et al. Prevalence and outcome of uveitis in a regional cohort of patients with juvenile rheumatoid arthritis. J Rheumatol. 1997; 24: 2031-2034.
19. Cabral DA, Petty RE, Malleson PN, et al. Visual prognosis in children with chronic anterior uveitis and arthritis.J Rheumatol. 1994; 21:2370-2375.
20. Petty RE. Current knowledge of the etiology and pathogenesis of chronic uveitis accompanying juvenile rheumatoid arthritis. Rheum Dis Clin North Am. 1987; 13:19-36.
21. Krumrey-Langkammerer M, Hafner R. Evaluation of the ILAR criteria for juvenile idiopathic arthritis. J Rheumatol. 2001; 28:2544-2547.
22. Stoll ML, Zurakowski D, Nigrovic LE, et al. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum. 2006; 54:3564-3572.
23. Zierhut M, Michels H, Stubiger N, et al. Uveitis in children. Int Ophthalmol Clin. 2005; 45:135-156.
24. Cabral DA, Oen KG, Petty RE. SEA syndrome revisited: a longterm followup of children with a syndrome of seronegative enthesopathy and arthropathy. J Rheumatol. 1992; 19:1282-1285.
25. Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol. 2002; 29:1520-1530.
26. Laaksonen A. A prognostic study of juvenile rheumatoid arthritis. Acta Pediatr Scand. 1966;(suppl 166): 163.
27. Moe N, Rygg M. Epidemiology of juvenile chronic arthritis in northern Norway: a ten-year retrospective study. Clin Exp Rheumatol. 1998; 16:99-101.
28. Rauz S, Murray PI, Southwood TR. Juvenile idiopathic arthritis and uveitis: the classification conundrum. Eye. 2000; 14(pt 6):817-820.
29. Chen CS, Roberton D, Hammerton ME. Juvenile arthritis-associated uveitis: visual outcomes and prognosis. Can J Ophthalmol. 2004; 39:614-620.
30. Grassi A, Corona F, Casellato A, et al. Prevalence and outcome of juvenile idiopathic arthritis-associated uveitis and relation to articular disease. J Rheumatol. 2007 ; 34: 1139-1145.
31. Kodsi SR, Rubin SE, Milojevic D, et al. Time of onset of uveitis in children with juvenile rheumatoid arthritis. J AAPOS. 2002; 6:373-376.
32. Oren B, Sehgal A, Simon JW, et al. The prevalence of uveitis in juvenile rheumatoid arthritis.J AAPOS. 2001; 5:2-4.
33. Singh S, Salaria M, Kumar L, et al. Clinico- immunological profile of juvenile rheumatoid arthritis at Chandigarh. Indian Pediatr. 1999; 36:449-454.
34. Carvounis PE, Herman DC, Cha S, et al. Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefes Arch Clin Exp Ophthalmol. 2006; 244:281-290.
35. Gare BA, Fasth A. The natural history of juvenile chronic arthritis: a population based cohort study. I. Onset and disease process.J Rheumatol. 1995; 22:295-307.
36. Kanski JJ. Screening for uveitis in juvenile chronic arthritis. Br J Ophthalmol. 1989; 73:225-228.
37. Dana MR, Merayo-Lloves J, Schaumberg DA, et al. Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology. 1997; 104:236-244.
38. Boone MI, Moore TL, Cruz OA. Screening for uveitis in juvenile rheumatoid arthritis.J Pediatr Ophthalmol Strabismus. 1998; 35:41-43.
39. Akduman L, Kaplan HJ, Tychsen L. Prevalence of uveitis in an outpatient juvenile arthritis clinic: onset of uveitis more than a decade after onset of arthritis. J Pediatr Ophthalmol Strabismus. 1997; 34:101-106.
40. Kazdan J J, McCulloch JC, Crawford JS. Uveitis in children. Can Med Assoc J. 1967; 96:385-391.
41. Perkins ES. Pattern of uveitis in children. Br J Ophthalmol. 1966; 50:169-185.
42. Ohno S, Char DH, Kimura SJ, et al. HLA antigens and antinuclear antibody utres in juvenile chronic iridocyclitis. Br J Ophthalmol. 1977; 61:59-61.
43. Saurenmann RK, Levin AV, Feldman BM, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum. 2007; 56:647-657.
44. Saurenmann RK, Rose JB, Tyrrell P, et al. Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. Arthritis Rheum. 2007; 56:1974-1984.
45. Kanski JJ. Juvenile arthritis and uveitis. Surv Ophthalmol. 1990; 34:253-267.
46. Ravelli A, Felici E, Magni-Manzoni S, et al. Patients with antinuclear antibody- positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum. 2005; 52:826-832.
47. Lawrence J M III, Moore T L, Osborn TG, et al. Autoantibody studies in juvenile rheumatoid arthritis. Semin Arthritis Rheum. 1993; 22:265-274.
48. Leak AM. Autoantibody profile in juvenile chronic arthritis. Ann Rheum Dis. 1988; 47:178-182.
49. van Rossum M, van Soesbergen R, de Kort S, et al. Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. J Rheumatol. 2003; 30:825-828.
50. Low JM, Chauhan AK, Kietz DA, et al. Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis. J Rheumatol. 2004; 31:1829-1833.
51. Kwok JS, Hui KH, Lee TL, et al. Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol. 2005; 34:359-366.
52. van Boekel MA, Vossenaar ER, van den Hoogen FH, et al. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res. 2002; 4:87-93.
53. Grom AA, Hirsch R. T-cell and T-cell receptor abnormalities in the immuno- pathogenesis of juvenile rheumatoid arthritis. Curr Opin Rheumatol. 2000; 12: 420-424.
54. Fife MS, Gutierrez A, Ogilvie EM, et al. Novel IL10 gene family associations with systemic juvenile idiopathic arthritis. Arthritis Res Ther. 2006; 8:R148.
55. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998; 102: 1369-1376.
56. de Benedetti F, Massa M, Robbioni P, Ravelli A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991; 34:1158-1163.
57. Jarvis JN, Jiang K, Petty HR, et al. Neutrophils: the forgotten cell in JIA disease pathogenesis. Pediatr Rheumatol Online J. 2007; 5:13.
58. Foell D, Wittkowski H, Hammerschmidt I, et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum. 2004; 50:1286-1295.
59. Moroldo MB, Tague BL, Shear ES, et al. Juvenile rheumatoid arthritis in affected sibpairs. Arthritis Rheum. 1997; 40:1962-1966.
60. Savolainen A, Saila H, Kotaniemi K, et al. Magnitude of the genetic component in juvenile idiopathic arthritis. Ann Rheum Dis. 2000; 59:1001.
61. Donn RP, Oilier WE. Juvenile chronic arthritis-a time for change? Eur J Immuno- genet. 1996; 23:245-260.
62. Prahalad S. Genetics of juvenile idiopathic arthritis: an update. Curr Opin Rheumatol. 2004; 16:588-594.
63. Forre O, Smerdel A. Genetic epidemiology of juvenile idiopathic arthritis. Scand J Rheumatol. 2002; 31:123-128.
64. Zeggini E, Donn RP, Oilier WE, et al. Evidence for linkage of HLA loci in juvenile idiopathic oligoarthritis: independent effects of HLA-A and HLA-DRB1. Arthritis Rheum. 2002; 46:2716-2720.
65. Zeggini E, Packham J, Donn R, et al. Association of HLA-DRB1*13 with susceptibility to uveitis in juvenile idiopathic arthritis in two independent data sets. Rheumatology (Oxford). 2006; 45:972-974.
66. Chia A, Lee V, Graham EM, et al. Factors related to severe uveitis at diagnosis in children with juvenile idiopathic arthritis in a screening program. Am J Ophthalmol. 2003; 135:757-762.
67. Edelsten C, Lee V, Bendey CR, et al. An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood. Br J Ophthalmol. 2002; 86:51-56.
68. Kanski JJ. Uveitis in juvenile chronic arthritis: incidence, clinical features and prognosis. Eye. 1988; 2(Pt 6):641-645.
69. Keenan J D, Goldstein DA, Tessler H H. Granulomatous inflammation in Juvenile Idiopathis Arthritis. Invest Ophthalmol Vis Sci. 2007. E-abstract.
70. Foster CS. Diagnosis and treatment of juvenile idiopathic arthritis-associated uveitis. Curr Opin Ophthalmol. 2003; 14:395-398.
71. Berk AT, Kocak N, Unsal E. Uveitis in juvenile arthritis. Ocul Immunol Inflamm. 2001; 9:243-251.
72. Woreta F, Thorne JE, Jabs DA, et al. Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol. 2007;143:647-655.
73. Sijssens KM, Rothova A, Berendschot 11, et al. Ocular hypertension and secondary glaucoma in children with uveitis. Ophthalmology. 2006;113:853-859. e2.
74. Hoffmann AL, Milman N, Byg KE. Childhood sarcoidosis in Denmark 1979-1994: incidence, clinical features and laboratory results at presentation in 48 children. Acta Paediatr. 2004;93:30-36.
75. Weinberg I, Vasiliev L, Gotsman I. Anti-dsDNA antibodies in sarcoidosis. Semin Arthritis Rheum. 2002;29:328-331.
76. American Academy of Pediatrics Section on Rheumatology and Section on Ophthalmology. Guidelines for ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics. 1993;92:295-296.
77. Ceisler EJ, Foster CS. Juvenile rheumatoid arthritis and uveitis: minimizing the blinding complications. Int Ophthalmol Clin. 1996;36:91-107.
78. Kanski JJ. Anterior uveitis in juvenile rheumatoid arthritis. Arch Ophthalmol. 1977;95:1794-1797.
79. Nguyen QD, Foster CS. Saving the vision of children with juvenile rheumatoid arthritis-associated uveitis. JAMA. 1998;280:1133-1134.
80. Hoemagel D. Toxic effects of atropine and homatropine eyedrops in children. N Engl J Med. 1961;264:168-171.
81. Iwao K, Inatani M, Kawaji T, et al. Frequency and risk factors for intraocular pressure elevation after posterior sub-Tenon capsule triamcinolone acetonide injection./ Glaucoma. 2007;16:251-256.
82. Kwok AK, Lam DS, Ng JS, et al. Ocular-hypertensive response to topical steroids in children. Ophthalmology. 1997;104:2112-2116.
83. Brunner HI, Kim KN, Ballinger SH, et al. Current medication choices in Juvenile Rheumatoid Arthritis II -update of a survey performed in 1993.J Clin Rheumatol. 2001;7:295-300.
84. Lee DH, Daud U, Wipfl J, et al. The decreasing prevalence of uveitis associated with juvenile rheumatoid arthritis: do NSAIDs play a role? J Clin Rheumatol. 2003;9:151-155.
85. Shah SS, Lowder CY, Schmitt MA, et al. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology. 1992;99:1419-1423.
86. Dev S, McCallum RM, Jaffe GJ. Methotrexate treatment for sarcoid- associated panuveitis. Ophthalmology. 1999; 106:111-118.
87. Bom S, Zamiri P, Lightman S. Use of methotrexate in the management of sight- threatening uveitis. Ocul Immunol Inflamm. 2001; 9:35-40.
88. Cron RQ, Sherry DD, Wallace CA. Methotrexate -induced hypersensitivity pneumonitis in a child with juvenile rheumatoid arthritis. J Pediatr. 1998; 132: 901-902.
89. Takeyama J, Sato A, Nakano K, et al. Epstein- Barr virus associated Hodgkin lymphoma in a 9-year-old girl receiving long-term methotrexate therapy for juvenile idiopathic arthritis. J Pediatr Hematol Oncol. 2006; 28:622-624.
90. Ravelli A, Moretti C, Temporini F, et al. Combination therapy with methotrexate and cyclosporine A in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002; 20: 569-572.
91. Wolf MD, Lichter PR, Ragsdale CG. Prognostic factors in the uveitis of juvenile rheumatoid arthritis. Ophthalmology. 1987; 94:1242-1248.
92. Waheed NK, Miserocchi E, Foster CS. Ocular concerns in juvenile rheumatoid arthritis. Int Ophthalmol Clin. 2001; 41:223-234.
93. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. Ophthalmology. 1996; 103:365-373; discussion 373-374.
94. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993; 34:1081-1085.
95. Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm. 2005; 13:335-351.
96. de Vos AF, van Haren MA, Verhagen C, et al. Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin- induced uveitis in the rat. Invest Ophthalmol Vis Sci. 1994; 35:1100-1106.
97. Planck SR, Huang XN, Robertson JE, et al. Cytokine mRNA levels in rat ocular tissues after systemic endotoxin treatment. Invest Ophthalmol Vis Sci. 1994; 35: 924-930.
98. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53:18-23.
99. Foeldvari I, Nielsen S, Kummerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol. 2007;34: 1146-1150.
100. Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45:252-257.
101. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr. 2006; 149:572-575.
102. Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum. 2004;50:1040-1050.
103. Botsios C. Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmun Rev. 2005;4:162-170.
104. Klapman JB, Ene-Stroescu D, Becker MA, et al. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis. 2003;9:176-178.
105. Bondeson J, Maini RN. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE). Int J Clin Pract. 2001;55:211-216.
106. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford). 2002; 41:1428-1435.
107. Flynn HW Jr, Davis JL, Culbertson WW. Pars plana lensectomy and vitrectomy for complicated cataracts in juvenile rheumatoid arthritis. Ophthalmology. 1988; 95:1114-1119.
108. Probst LE, Holland EJ. Intraocular lens implantation in patients with juvenile rheumatoid arthritis. Am J Ophthalmol. 1996; 122:161-170.
109. Foster CS, Barrett F. Cataract development and cataract surgery in patients with juvenile rheumatoid arthritis-associated iridocyclitis. Ophthalmology. 1993; 100: 809-817.
110. Lam LA, Lowder CY, Baerveldt G, et al. Surgical management of cataracts in children with juvenile rheumatoid arthritis-associated uveitis. Am J Ophthalmol. 2003; 135:772-778.
111. Li J, Heinz C, Zurek-Imhoff B, et al. Intraoperative intraocular triamcinolone injection prophylaxis for post-cataract surgery fibrin formation in uveitis associated with juvenile idiopathic arthritis.J Cataract Refract Surg. 2006; 32:1535-1539.
112. Kanski J J, McAllister JA. Trabeculodialysis for inflammatory glaucoma in children and young adults. Ophthalmology. 1985; 92:927-930.